Top Medical News

5-Year Survival Data Showcases Long-Term Benefit With Nivolumab/Ipilimumab-Treated Metastatic NSCLC

June 12th 2022

Frontline nivolumab and ipilimumab combination therapy was associated with increased 5-year survivorship in patients with metastatic non–small cell lung cancer—regardless of PD-L1 expression.

Frontline Bevacizumab Prolongs PFS, OS in Ovarian Clear Cell Carcinoma

June 11th 2022

Ovarian clear cell carcinoma is a rare histological type of epithelial ovarian cancer that is typically resistant to chemotherapy and is historically associated with poor prognosis for patients.

Forgetfulness A Significant Barrier to Oral Adherence in Elderly Patients With Prostate Cancer

June 10th 2022

Elderly patients receiving novel-androgen hormonal therapies, such as abiraterone and enzalutamide, listed forgetfulness as their No. 1 reason for not taking prescribed pills.

Updated PFS Data Continue to Support Nivolumab Plus Relatlimab in Advanced Melanoma

June 10th 2022

Relatlimab, a human LAG-3 blocking antibody, plus nivolumab, elicited superior progression-free survival in patients with advanced melanoma compared to nivolumab alone.

Adagrasib Associated With Promising Disease Control Rate in KRAS G12C–Mutant NSCLC

June 9th 2022

Investigators reported an objective response rate of 43% and a disease control rate of 80% among patients with previously treated KRAS G12C–mutated non–small cell lung cancer who received the KRAS G12C inhibitor adagrasib.

Most Recent